

Pen peptide certificate of analysis (CoA)

Product:	Ipamorelin		
Source:	Hybrid synthesis (recombinant using peptide secretion system and chemical synthesis)		
Intended use:	For stability, viability and activity testing only.		
Order number:		Lot:	25AUG08IPA
Production:	08/2025	Expiry:	08/2027
Formulation:	0.2 µm-filtered solution in 20mM glycine, 200mM Mannitol, 20mM NaH ₂ PO ₄ , pH 7.4; m-cresol 1 mg/ml, glycerol 2 mg/ml (when liquid)		
Protein/peptide concentration per 3 ml cartridge:	15 mg		

<u>Release Testing:</u>	<u>Specification</u>	<u>Lot Result</u>
Purity:	≥ 97%	> 98%
Identity:	Complies	Complies
Sterility:	Sterile	Complies
Endotoxin level:	< 10 EU/mg	< 0.20 EU/mg
Host-cell DNA	≤ 200 ng/mg	Complies (1.1 ng/mg)

Activity was determined using in vitro test.

Purity was determined by HPLC.

Identity was confirmed by end-of-production DNA sequencing and N-terminal protein sequencing.

Sterility test of vial product was performed according to Eur.Pharm. (Inoculation method).

Endotoxin was determined using the gel clot assay according to Eur.Pharm.

Host-cell DNA/RNA was determined using fluorimetric assay (if applicable).

Handling Instructions:

General usage: Open cap, clean the rubber stopper with disinfectant napkin or other cleaning disinfection method / material. Puncture rubber stopper with sterile needle by screwing needle on. Remove the plastic protective cover. Set the index to physician prescribed position, remove the pink plastic cover and let out the air from the cartridge by several button presses into the air. Put on the plastic protective cover back.

Using liquid product: Liquid products are ready to use according to physician recommendations.

Storage and stability: Store material at +2 - +8°C. **Do not freeze!**

Quality Statement:

This product is manufactured, tested and realized in compliance with the relevant GMP-guidelines. No animal- or human-derived materials were used during manufacturing. USP chapter <1043> “ancillary materials for cell, gene, and tissue-engineered product” has been considered in the design of this product.

Single Injection Report



Data file: 2025-08-08 05-21-52+08-00-05-r002.dx

Sequence Name: Agilent-1-2024-10-15 22-41-32+08-00 **Project Name:** Ipamorelin

Sample name: 20250808-Ipamorelin-0.2070MG/ML- C81 **Operator:** SYSTEM (SYSTEM)


Instrument: Agilent-1 **Injection date:** 2025-08-08 05:22:33+08:00

Inj. volume: 10.000 µL **Location:** P2-C3

Acq. method: TEP.amx **Type:** Sample

Processing method: TFA.pmx **Sample amount:** 0.00


Manually modified: Manual Integration



Signal: VWD1A,Wavelength=220 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
9.438	MM m	0.27	9.62	1.45	0.11	
10.068	MM m	0.52	9114.02	1308.16	99.71	
10.382	MM m	0.29	10.17	1.43	0.11	
10.775	MM m	0.22	2.30	0.27	0.03	
11.900	MM m	0.18	1.28	0.23	0.01	
12.199	MM m	0.19	1.73	0.29	0.02	
13.699	MM m	0.21	1.23	0.19	0.01	
		Sum	9140.35			

20250808-Ipamorelin 18 (0.306)
Scan ES+



1.91e8
A: 711.98±0.33

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #56958

Testing ordered > 29 JAN '25

Sample received > 29 JAN '25

Client Pen Peptides

Sample Ipamorelin 10 mg in 2 ml

Manufacturer Unknown

Batch Unknown

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide cartridge

Results >



Ipamorelin	4.89 mg/ml
Purity	99.729%

Comments >

Analysis conducted > 03 FEB 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

J6ICIMEJ23G1